Gemin X Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company developing focused on modulating apoptotic therapeutics for hematological and solid tumors, including chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $16M Series D financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.